All
PolyPEPI1018 Boosts Efficacy of Atezolizumab in Metastatic MSS CRC
Published: June 3rd 2024 | Updated: June 3rd 2024PolyPEPI1018 given in combination with atezolizumab showed tolerability and induced immune responses in patients with relapsed/refractory microsatellite-stable metastatic colorectal cancer.
Analysis Shows Low Risk of Progression With Darolutamide in nmCRPC
June 2nd 2024Based on a post-hoc analysis of the ARAMIS trial, darolutamide was associated with lower rates of PSA and radiological progression vs placebo as well as improving overall survival in patients with nonmetastatic castration-resistant prostate cancer.
Real-World Sacituzumab Govitecan Yields Lower ORR Post-EV in mUC
June 2nd 2024A retrospective cohort of patients with metastatic urothelial cancer who received prior enfortumab vedotin had low efficacy when treated with sacituzumab govitecan, with the best outcomes coming from direct sequencing the two agents.